GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Change In Receivables

West Pharmaceutical Services (West Pharmaceutical Services) Change In Receivables

: $0 Mil (TTM As of Dec. 2023)
View and export this data going back to 1980. Start your Free Trial

West Pharmaceutical Services's change in receivables for the quarter that ended in Dec. 2023 was $0 Mil. It means West Pharmaceutical Services's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

West Pharmaceutical Services's change in receivables for the fiscal year that ended in Dec. 2023 was $4 Mil. It means West Pharmaceutical Services's Accounts Receivable declined by $4 Mil from Dec. 2022 to Dec. 2023 .

West Pharmaceutical Services's Accounts Receivable for the quarter that ended in Dec. 2023 was $512 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. West Pharmaceutical Services's Days Sales Outstanding for the three months ended in Dec. 2023 was 63.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. West Pharmaceutical Services's liquidation value for the three months ended in Dec. 2023 was $507 Mil.

West Pharmaceutical Services Change In Receivables Historical Data

The historical data trend for West Pharmaceutical Services's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

West Pharmaceutical Services Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.30 -46.60 -123.50 -35.60 4.00

West Pharmaceutical Services Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Change In Receivables Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

West Pharmaceutical Services Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services  (NYSE:WST) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

West Pharmaceutical Services's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=512/732*91
=63.83

2. In Ben Graham's calculation of liquidation value, West Pharmaceutical Services's accounts receivable are only considered to be worth 75% of book value:

West Pharmaceutical Services's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=853.9-948.5+0.75 * 512+0.5 * 434.7
=507

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

West Pharmaceutical Services Change In Receivables Related Terms

Thank you for viewing the detailed overview of West Pharmaceutical Services's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

West Pharmaceutical Services (West Pharmaceutical Services) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » West Pharmaceutical Services Inc (NYSE:WST) » Definitions » Change In Receivables
Comparable Companies
RMD BAX COO HOLX TFX RGEN ATR STVN XRAY MMSI ISRG XPAR:EL BDX TSE:7741 XSWX:ALC OCSE:COLO B XPAR:DIM TSE:4543 XSWX:STMN TSE:7733
Traded in Other Exchanges
WPS:Germany
Address
530 Herman O. West Drive, Exton, PA, USA, 19341-0645
Website
https://www.westpharma.com
West Pharmaceutical Services is a Pennsylvania-based medical supplies company that operates as a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West develops, manufactures, and distributes elastomer-based supplies for the containment and administration of injectable drugs, including basic equipment such as syringes, stoppers, and plungers, along with somewhat more complicated devices including auto-injectors and other self-injection platforms. The company reports in two segments: proprietary products (82% of 2021 sales) and contract-manufactured products (18%). It generates 55% of its revenue from international markets and 45% from the United States.
Executives
Chad Winters officer: VP, CAO & Controller 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Charles Witherspoon officer: VP & Treasurer 530 HERMAN O WEST DRIVE, EXTON PA 19341
Annette F Favorite officer: Sr. VP Human Resources Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Cindy Reiss-clark officer: Senior Vice President 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147
Quintin J Lai officer: VP Corp Development & Strategy 530 HERMAN 0. WEST DRIVE, EXTON PA 19341
Silji Abraham officer: Chief Digital & Trans Officer 5000 TOWN CENTER, U, SOUTHFIELD MI 48075
Eric Mark Green officer: Chief Executive Officer 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Bernard Birkett officer: Sr VP, CFO & Treasurer 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Thomas W Hofmann director FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087
Stephen H Lockhart director C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508
Molly Joseph director 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620
Kimberly Banks Mackay officer: SVP, GC & Corporate Secretary 530 HERMAN O. WEST DRIVE, EXTON PA 19341
George Lloyd Miller officer: Sr. VP, GC & Corp. Sec. 530 HERMAN O. WEST DRIVE, EXTON PA 19341
David A Montecalvo officer: SVP, Glob Ops and Supply Chain 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Robert F Friel director 940 WINTER STREET, WALTHAM MA 02451